NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose: To evaluate the efficacy, tolerability and safety of NS1209 compared to lidocaine and placebo in patients with peripheral chronic neuropathic pain.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Danish Pain Research Center
• Collaborator: NeuroSearch A/S
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• Age >18 years

• Neuropathic pain and allodynia after a peripheral nerve injury (VAS >= 4)

Exclusion Criteria:

• Patients who cannot cooperate and do no understand Danish

• Fertile women

• Clinically significant abnormality or disease

• Drug and alcohol abuse

• Clinically abnormal ECG

• Hypersensitivity to any of the treatments

• Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics except gabapentin, anticoagulants, Na channel blockers and beta blockers

• Patients who have previously been treated in a NS1209 study

• Patients treated with an investigational drug